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More than 150 familial Alzheimer disease (FAD)-associated
missense mutations in presenilins (PS1 and PS2), the catalytic
subunit of the -secretase complex, cause aberrant amyloid
-peptide (A) production, by increasing the relative produc-
tion of the highly amyloidogenic 42-amino acid variant. The
molecular mechanism behind this pathological activity is
unclear, and different possibilities ranging from a gain of func-
tion to a loss of functionhave beendiscussed.-Secretase, signal
peptide peptidase (SPP) and SPP-like proteases (SPPLs) belong
to the same family of GXGD-type intramembrane cleaving
aspartyl proteases and share several functional similarities. We
have introduced the FAD-associated PS1 G384A mutation,
which occurs within the highly conserved GXGD motif of PS1
right next to the catalytically critical aspartate residue, into the
corresponding GXGDmotif of the signal peptide peptidase-like
2b (SPPL2b). Compared with wild-type SPPL2b, mutant
SPPL2b slowed intramembrane proteolysis of tumor necrosis
factor  and caused a relative increase of longer intracellular
cleavage products. Because the N termini of the secreted coun-
terparts remain unchanged, the mutation selectively affects the
liberation of the intracellular processing products. In vitro
experiments demonstrate that the apparent accumulation of
longer intracellular cleavage products is the result of slowed
sequential intramembrane cleavage. The longer cleavage prod-
ucts are still converted to shorter peptides, however only after
prolonged incubation time. This suggests that FAD-associated PS
mutation may also result in reduced intramembrane cleavage of
-amyloid precursor protein (APP). Indeed, in vitro experiments
demonstrate slowed intramembrane proteolysis by -secretase
containingPS1with theG384Amutation.As comparedwithwild-
type PS1, the mutation selectively slowed A40 production,
whereas A42 generation remained unaffected. Thus, the PS1
G384Amutation causes a selective loss of function by slowing the
processing pathway leading to the benign A40.
Research on the proteolytic generation of the Alzheimer’s
disease (AD)3-associated amyloid -peptide (A) from its pre-
cursor, the -amyloid precursor protein (APP) paved the way
to the concept of regulated intramembrane proteolysis (1).
Already early work suggested that, upon ectodomain shedding
of APP, the remaining membrane-retained stub, the APP
C-terminal fragment undergoes intramembrane proteolysis by
a physiologically normal mechanism (2–4) (Fig. 1). Intramem-
brane proteolysis is now known for many substrates and either
required for the generation of a transactivating intracellular
domain (ICD) or for a rather general removal of membrane-
retained protein stubs (a membrane proteasome function) (5).
The intramembrane cleaving protease ofAPP turned out to be
a high molecular weight complex, termed -secretase, which is
composed of four subunits, presenilin (PS1 or PS2), Nicastrin,
APH-1a/b, and PEN-2 (6). The four components are required
and sufficient for -secretase activity (7). PSs share a common
active site motif within transmembrane domain (TM) 7, the
GXGD motif (8, 9). This motif is also present in several other
proteases such as the type IV prepilin peptidases, the signal
peptide peptidase (SPP), and the SPP-like proteases (SPPL2a,
SPPL2b, and SPPL3) (10, 11) and now defines the novel class of
GXGD-type intramembrane cleaving aspartyl proteases (8). In
contrast to -secretase, members of the SPP family appear not
to require additional components but are rather proteolytically
active by themselves (10, 12). In addition, SPP family members
exclusively accept transmembrane proteins in a type II orienta-
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tion as substrates (10, 12–15), whereas for -secretase only
type-I-oriented substrates have been described so far (Fig. 1)
(6). The SPP family members are differentially distributed
within the secretory pathway (14, 16), a fact that may reflect
their preference for certain substrates located within the
respective compartments. Consistentwith that hypothesis, SPP
is found within the endoplasmic reticulum, where it is involved
in the degradation of signal peptides. Besides degradation of
signal peptides, SPP is also involved in immune surveillance,
intramembrane processing of the hepatitis C virus core protein
(10), and dislocation from the endoplasmic reticulum (17). For
the Golgi and endosome/lysosome-located SPPL2a and its
close homologue SPPL2b, so far three different substrates have
been identified, tumor necrosis factor  (TNF) (12, 14), the
Fas-ligand (13), and Bri2 (British dementia protein-2 or Itm2b)
(15). Intramembrane proteolysis of TNF leads to the genera-
tion of an ICD, which is required for reverse signaling and reg-
ulation of interleukin-12 levels (14). Interestingly, both-secre-
tase and SPPL2b substrates undergo multiple and similar
intramembrane cleavages (12, 18) (Fig. 1). For -secretase it
appears that a cleavage oriented more toward the cytoplasm
(-cleavage) leads to the liberation of an ICD (19–21), whereas
additional cleavages (- and -cleavages) in the middle of the
membrane are required to finally release small peptides, includ-
ing A into the extracellular space (6, 22) (Fig. 1). Because SPP
family members cleave type-II proteins (Fig. 1) and their prote-
ase active sites are in the opposite orientation as those of PS
(23), onemay also expect opposite cleavage reactions, a hypoth-
esis that is supported by the results presented in this study.
PSs contain the most frequently observed FAD-associated
mutations (6). Until now more than 150 PS mutations have
been described, which probably all cause early onset AD by a
subtle shift of the -cleavage within TM of APP from position
40 to position 42 of A. The 42-amino acid A42 is highly
prone to aggregation and forms neurotoxic A oligomers,
which affect long term potentiation and neuronal survival (24).
The exact molecular mechanism behind this shift in cleavage
precision is currently unclear. However, evidence exists that PS
mutations may affect the proximity
of the PS N-terminal and C-termi-
nal fragment within the active
-secretase complex (25). This may
indicate that PS mutations induce
structural changes affecting the
protease active site embedded
withinTM6of the PSNTF andTM7
of the PSC-terminal fragment. Early
work already demonstrated that
FAD-associated PSmutations fail to
rescue the Notch phenotype caused
by the loss of the PS homologue in
Caenorhabditis elegans while wt
human PS was fully functional (26,
27). Moreover, several rather ag-
gressive PS mutations have been
described, which strongly inhibit
the production of the Notch ICD
(28). Nevertheless at least some PS
mutations appear to rescue the Notch phenotype observed in
PS knockout mice (29). Thus, it is unclear if FAD-associated PS
mutations cause a loss or a (toxic) gain of function (30–32).
Insights into the pathological mechanisms of PS mutations are
highly important not only for the understanding of FAD but
also for future treatment strategies aiming to inhibit -secre-
tase activity. We have now introduced the FAD-associated PS1
G384Amutation (9) into the homologous and highly conserved
motif of SPPL2b. Surprisingly, this results in the accumulation
of a longer ICD, which was produced by a slowed sequential
cleavage within the membrane of the SPPL2b substrate TNF.
Similar findings were made with the PS1 G384A mutation,
which in comparison to wt PS1 exhibits a selectively slowed
production of A40, whereas the rate of A42 generation is
largely unaffected.
EXPERIMENTAL PROCEDURES
Cell Culture, cDNAs, and Transfection—HEK 293 TR cells
(InvitrogenGmbH, Karlsruhe, Germany) were cultured in Dul-
becco’s modified Eagle’s medium with Glutamax (Invitrogen)
supplemented with 10% fetal calf serum (Invitrogen), 5 g/ml
blasticidin (Invitrogen), and 1% penicillin/streptomycin
(Invitrogen). Using PCR, a HA tag (AYPYDVPDYA) and a stop
codonwere added to theC termini of all constructs. SPPL2bwt,
SPPL2b D421A, and SPPL2b G420A were subcloned into the
EcoRI and XhoI sites of pcDNA 4/TO/myc/his A (Invitrogen)
and stably transfected into HEK 293 TR cells. Transfection of
cells was carried out using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions, and single cell
clones were generated by selection in 200 g/ml Zeocin
(Invitrogen). To induce expression of the SPPL2b constructs,
cells were incubatedwith 1g/ml doxycycline (BDBiosciences,
San Jose, CA) added to the cell culturemedium for at least 48 h.
HEK 293 cells stably co-expressing swAPP and PS1 wt or PS1
G384 have been described (28).
The TNF cDNA was obtained from ATCC (clone
AAA61198). Upon addition of a N-terminal FLAG tag (DYKD-
DDDK) after the starting methionine and a C-terminal HA tag
FIGURE 1. Intramembrane proteolysis of APP versus TNF. Schematic representation of the proteolytic
processing of APP and TNF by -secretase/PS1 and SPPL2b, respectively.
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(YPYDVPDYA) or a C-terminal V5 tag (GKPIPNPLLGLDST)
the TNF cDNA construct was subcloned into the HindIII/
XhoI sites of pcDNA 3.1. Hygro (Invitrogen). The C-termi-
nally truncated TNF E construct has been described before
(12). TNF cDNA constructs were co-transfected with the
respective SPPL2b variant using Lipofectamine 2000 (Invitro-
gen Life Sciences) according to the supplier’s instructions. All
cDNA constructs were sequenced for verification.
Antibodies, Immunoprecipitation, Immunohistochemical Stain-
ing, Immunoblotting, and Deglycosylation Experiments—The
monoclonal anti-HA antibody was obtained from Roche Diag-
nostics GmbH (Mannheim, Germany). The monoclonal anti-
FLAGM2 and the polyclonal HA 6908 antibody were obtained
fromSigma. Amonoclonal antibody to amino acids 536–557 of
SPPL2b was generated (CPSE-1H5). The monoclonal anti A
antibody 6E10 was purchased from Signet Laboratories. The
polyclonal antibody 6687 to the C terminus of APP has been
described (9). To separate individual A species a bis-Tricine-
urea gel-system described earlier was used (33). For the separa-
tion of TNF ICD species a modified Tris-Tricine gel was used
(12). Immunoprecipitation, deglycosylation, immunohisto-
chemical staining, and immunoblotting experiments were car-
ried out as described previously (12, 16).
TNF and C100 in Vitro Process-
ing Assays—TNF in vitro process-
ing assays were carried out as
described before (12). Where indi-
cated, cells were treated with the
SPPL2b inhibitor (Z-LL)2-ketone
(Calbiochem) (34) or protease in-
hibitor mixture (Sigma). Proteins
were immunoblotted and detected
using the enhanced chemilumines-
cence technique (GE Healthcare,
Little Chalfont, UK). For quantita-
tion the chemiluminescence sig-
nals of at least three independent
experiments were measured with a
CD camera-based imaging system
(Alpha Innotec, Kasendorf, Ger-
many). -Secretase in vitro assays
were carried out as described
using recombinant C100-His6
substrate (7). A partially purified
-secretase preparation was used
as enzyme source.4
Radiosequencing—HEK 293 cells
stably expressing SPPL2b wt and
transiently expressing TNFE
were metabolically labeled with
[3H]valine or [3H]leucine (Hart-
mann Analytic, Germany) for 16 h,
supernatants were collected, and
TNF C-domain peptides were
isolated by immunoprecipitation
with antibody HA6908 (Sigma)
separated by SDS-PAGE and
transferred to a polyvinylidene
difluoride membrane. Radiolabeled proteins were detected
by autoradiography, excised, and subjected to radiosequenc-
ing, essentially as described (3, 35).
RESULTS
Altered Proteolytic Processing of TNF by SPPL2b Carrying
an FAD-like Mutation—-Secretase and SPP/SPPL family
members share a number of similar biochemical properties (18,
36).Moreover, several sequencemotifs in the catalytic subunits
of -secretase, PS1 or PS2, and SPP family members are con-
served. These include the two active site domains, the YD and
GXGDmotif in TM6 and TM7, as well as a PALmotive in TM9
(10, 11, 16), which likely also contributes to the catalytic site
(37). A very aggressive FAD-associated PS1 mutation (PS1
G384A) immediately N-terminal to the critical aspartate resi-
due in TM7 of PS1 helped to elucidate the importance of the
GXGDdomain for PS and led to the definition of the new family
of GXGD-type aspartyl proteases (8, 9). The PS1 G384Amuta-
tion (Fig. 2A) strongly affects the precision of the -secretase
cleavage causing a substantial relative increase of pathological
A42 (9, 38). To prove if such a single amino acid exchange
4 Winkler et al., manuscript in preparation.
FIGURE 2. Proteolytic processing of TNF by SPPL2b. A, amino acid alignment of PS1 and SPPL2b. Amino
acids of TM 7 of PS1 and SPPL2b are depicted using the single letter code. The conserved GXGD motive in the
catalytically active site of PS1 and SPPL2b is highlighted by the gray box. The mutagenized glycine residue in
PS1 and SPPL26 is shown in bold. B, post-translational maturation of SPPL2b variants. Protein extracts of HEK
293 cells stably expressing the indicated SPPL2b variants were treated with N-glycosidase F (N-Gly F) or
endoglycosidase H (EndoH). SPPL2b variants were detected using the monoclonal anti-HA antibody (Roche
Applied Science). Note endoglycosidase H resistance of all SPPL2b variants. C, cellular localization of SPPL2b
variants. Immunohistochemical staining of SPPL2b wt and SPPL2b G420A using the polyclonal anti HA-anti-
body. SPPL2b wt and SPPL2b G420A show identical subcellular localization. D, TNF ICD generation. HEK 293
cells stably expressing the indicated SPPL2b variants were transiently transfected with full-length TNF. Cel-
lular membranes were isolated, incubated for 15 min at 37 °C, and subjected to SDS-PAGE and Western blot
analysis. TNF N-terminal fragments were visualized using the anti-FLAG antibody. Expression levels of SPPL2b
variants are shown in the lower panel. Note that the TNF ICD detected in SPPL2b G420A-expressing cells
migrates slower than the ICDs detected in SPPL2b wt-expressing cells. E, pharmacological inhibition of SPPL2b
G420A prevents TNF ICD generation. Membranes of HEK 293 cells described in D were isolated and incubated
in the presence of 15 M (Z-LL)2-ketone or the respective carrier for 15 min at 37 °C. TNF N-terminal fragments
were detected as described in D. Note that (Z-LL)2-ketone treatment inhibits TNF ICD generation in SPPL2b wt
and in SPPL2b G420A-expressing cells to the same extent.
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could also affect the cleavage precision of other GXGD-type
aspartyl proteases, the corresponding conserved glycine resi-
due in SPPL2b was mutagenized to alanine, creating SPPL2b
G420A (Fig. 2A). Like wt SPPL2b, the SPPL2b G420A mutant
became endoglycosidase H-resistant upon expression in HEK
293 cells, which is consistent with normal transport through
the secretory pathway (Fig. 2B). Moreover, mutant and wt
SPPL2b showed a similar distribution within the secretory
pathway, including a giantin-positive Golgi compartment (Fig.
2C). Co-expression of TNF, the only SPPL2b substrate with a
known physiological function (14), allows monitoring of
intramembrane proteolysis (12). As reported before (12), wt
SPPL2b produces 6-kDa TNF ICD peptides (Fig. 2D). ICD
formation also occurs upon expression of the FAD-like SPPL2b
G420Amutation (Fig. 2D). Interestingly, the ICD peptides pro-
duced under these conditions by the SPPL2b G420A mutation
migrated at a slightly higher molecular weight (Fig. 2D). The
elongated TNF ICD peptide is a specific cleavage product of
SPPL2b G420A, because its generation is blocked by (Z-LL)2-
ketone, a selective inhibitor of the SPP-family (Fig. 2E) (10).
These findings may suggest that the FAD-like mutation
exhibits an altered activity, which in analogy to mutant PS
may lead to the generation of a slightly elongated cleavage
product. However, in clear contrast to the elongated A pep-
tide produced by mutant -secretase, this fragment accumu-
lates within cell lysates. Thus, consistent with the reverse
orientation of the active site motifs in TM6 and TM7 (23),
the products of intramembrane proteolysis of TNF by
SPPL2b are released into the opposite direction as compared
with -secretase substrates.
Mutant SPPL2b Does Not Affect the Generation of the
Secreted TNF C-domain—To prove the reverse release of
SPPL2b cleavage products as compared with -secretase cleav-
age products, we next analyzed the secreted TNF C-domain
(Fig. 1). Upon co-expression of the C-terminal HA-tagged
TNFE (12) with either SPPL2b wt or SPPL2b G420A the
TNF C-domain was secreted into the medium like in cells
expressing SPPL2bwt (Fig. 3A). Interestingly, and in contrast to
the ICDs, the TNF C-domains produced by wt and G420A
mutant SPPL2b co-migrated suggesting equal cleavage sites
(Fig. 3A). To ensure that the C-domain species secreted from
the two cell lines are indeed produced by endoproteolytic cleav-
age at identical sites we radiosequenced their N termini.
Sequencing the N termini of the secreted C-domain species
from either SPPL2b wt- or SPPL2b G420A-expressing cells
revealed no difference in the cleavage site (Fig. 3B). Both,
mutant andwt SPPL2b produced peptideswithN termini start-
ing at leucine 50 or histidine 52. Both C-domain species pro-
duced by each cell line (Fig. 3A) were radiosequenced and dem-
onstrated to have identical N termini (data not shown). Thus
differences in the running behavior are either due to aberrant
folding or the lack of a few amino acids on the C termini of the
faster migrating species. These findings suggest that an FAD-
like mutation in SPPL2b shifts the intramembrane cleavage of
its substrate like mutant -secretase. However, consistent with
the opposite orientation of the protease active site domains (23)
and the type-II orientation of the TNF substrate, the elon-
gated product was not secreted like A42 but released into the
cytosol (Fig. 2D). Thus, our findings demonstrate that the mal-
function of FAD-associated PS mutations can be transferred to
other members of the GXGD-type proteases. Moreover, our
findings provide direct evidence for a reversed orientation/ac-
tivity of SPPL2b.
Mutant SPPL2b Slows Sequential Intramembrane Proteolysis—
To investigate a putative stepwise conversion of TNF into its
ICD fragments as it has been suggested for -secretase cleavage
of APP (22, 39–41) we performed in vitro processing experi-
ments.Membranes of cells co-expressingwt SPPL2bor SPPL2b
G420A and TNF were incubated for various time points, and
cleavage products were separated on Tris-Tricine gels. Surpris-
ingly, this revealed that both wt and mutant SPPL2b variants
initiate intramembrane proteolysis of TNF with the produc-
tion of a co-migrating peptide, designated ICD peptide 1 (Fig.
4A). At 1 h, ICD peptide 1 was rapidly processed by wt SPPL2b
via an intermediate peptide (ICD peptide 2) to the fast migrat-
ing ICD peptide 3 (Fig. 4A). In contrast, ICD peptide 1 was
significantly slower turned over by SPPL2b G420A. Only after
6 h of incubation, ICD peptide 1 was at least partially turned
over to ICD peptide 2, but at this time point no ICD peptide 3
was observed (Fig. 4A). Moreover, the TNF NTF, which rep-
resents the immediate substrate for SPPL2b, was rapidly turned
FIGURE 3. The C-domain liberated from SPPL2b G420A-expressing cells is
unchanged as compared with SPPL2b wt. A, generation of the TNF C-do-
main. Conditioned media of HEK 293 cells stably expressing the indicated
SPPL2b variants and transiently expressing TNFE (12) were analyzed for
the TNF C-domain using antibodies against the HA tag. Note that the TNF
C-domain species secreted in cells expressing SPPL2b wt and in cells express-
ing SPPL2b G420A show identical running behavior. B, radiosequencing of
the TNF C-domain in SPPL2b G420A mutant cell lines. Cell lines described in
A were labeled with either [3H]valine () or [3H]leucine (). Radiosequencing
of the isolated TNF C-domain reveals identical TNF C-domain species in
both cell lines starting at Leu-50 or His-52. Both C-domain species detected in
A have the same N terminus and probably slightly differ in either their C
terminus or their structure.
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over by wt SPPL2b, whereas this fragment accumulated in cells
expressing the G420A mutation (Fig. 4, A and B). Very similar
findingswere observedwhen independent cell cloneswere used
(data not shown). This suggests that mutant SPPL2b is proteo-
lytically active but may exhibit a reduced turnover rate. If that
was the case onewould expect that, upon prolonged incubation
time periods,mutant SPPL2b should be capable of producing at
least some ICD peptide 3. Indeed, upon 22 h of incubation, a
peptide co-migrating with ICD peptide 3 was produced by cells
expressing SPPL2bG420A at least to some extend (supplemen-
tal Fig. S1). Moreover, whenmembranes of cells co-expressing
wt SPPL2b and TNF were incubated at lower temperature
to mimic reduced turnover, TNF NTF also accumulated
over time (Fig. 4C). Thus, if wt SPPL2b is incubated under
suboptimal conditions, reduced processing of the TNF
NTF and the resulting TNF ICD peptides leads to an
altered ratio of long, intermediate,
and short ICD peptides, such as
those observed for the SPPL2b
G420A mutation.
The above-described findings do
not exclude the possibility that the
ICD peptides 2 and 3 are produced
by trimming proteases rather than
SPPL2b. Clearly the initial cleavage
is performed by SPPL2b, because
(Z-LL)2-ketone (see Fig. 2E) as well
as expression of the functional inac-
tive SPPL2b D421A mutation (16)
(Fig. 5A) inhibits its formation.
Moreover, co-incubation of mem-
brane fractions with a broad-spec-
trum protease inhibitor mixture
failed to significantly slow ICD
turnover (Fig. 5B). To finally prove
that SPPL2b is themajor converting
enzyme of all TNF ICD species, we
added (Z-LL)2-ketone after 0.2 h of
in vitro incubation to themembrane
fractions and analyzed ICD genera-
tion at the indicated time points
(Fig. 5C). Without addition of
(Z-LL)2-ketone, ICD peptide 2 con-
tinued to be turned over, whereas
the addition of (Z-LL)2-ketone
blocks conversion of the TNF ICD
species (compare ratios of ICD spe-
cies 2 and 3 in Fig. 5C at t  4 h),
demonstrating that all ICD pep-
tides were generated by the intrin-
sic proteolytic activity of SPPL2b.
Together with the data in Fig. 4
these findings therefore suggest a
sequential processing of TNF by
SPPL2b. However, in contrast to
wt SPPL2b, which rapidly pro-
duces the smaller ICD peptides,
mutant SPPL2b G420A shows a
significantly reduced turnover rate suggesting a partial loss
of function.
The FAD-associated PS1 G384A Selectively Slows A40
Generation—Similar in vitro experiments were then performed
with partially purified -secretase derived from cells expressing
PS1 wt or the PS1 G384Amutation. This revealed that -secre-
tase containing the PS1 G384A mutation shows a slowed turn-
over of the recombinant APP substrate C100-His6 in vitro as
compared with wt PS1, because AICD generation and produc-
tion of total Awere reduced (Fig. 6). However, comparison of
the time-dependent production of A40 and A42 by wt or
mutant -secretase revealed a selectively slowed A40 pro-
duction by -secretase containing the PS1 G384A mutation
(Fig. 5). Thus, slower A40 production by -secretase con-
taining the G384A PS1 mutant leads to the change in the
A42 to A40 ratio.
FIGURE 4. Conversion of the TNF ICD is slowed in cells expressing the SPPL2b G420A mutant. A, time-
dependent conversion of TNF ICD. Cellular membranes of HEK 293 cells co-expressing the indicated SPPL2b
variants and TNF FL were isolated and incubated for the indicated time periods at 37 °C. TNF ICD species
were separated using a modified Tris-Tricine gel and were visualized using the anti-FLAG antibody. Three
major TNF ICD species are detectable (designated 1–3). TNF ICD 1 is converted over time to ICD 2 and finally
to ICD 3. The conversion of TNF ICD 1 over time is significantly slower in cells expressing SPPL2b G420A
compared with cells expressing SPPL2b wt. Note the accumulation of TNF ICD 2 in SPPL2b G420A-expressing
cells. B, quantitative measurement of the TNF NTF conversion. The signal intensity of TNF NTF shown in A
was measured at the indicated time points of incubation and determined in relation to the TNF NTF signal at
time point 0. Values represent means  S.D. of three independent experiments. C, conversion of the TNF ICD
at reduced incubation temperature. TNF ICD conversion in membranes expressing SPPL2b wt is significantly
slower upon incubation at 20 °C as compared with incubation at 37 °C. Note the accumulation of TNF ICD 2
upon incubation at 20 °C.
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Until recently intramembrane proteolysis was thought to be
rather impossible, because watermolecules, which are required
for all proteolytic enzymes, are rare within the hydrophobic
lipid bilayer of themembrane.However, a surprising number of
intramembrane proteases have been identified during the last
few years (1, 43). These includemet-
alloproteases, such as site-2 pro-
teases (44), serine proteases, such as
the large family of rhomboids (43)
and aspartyl proteases, including
-secretase with PSs as catalytically
active subunits (45, 46), type 4
prepilin peptidases (47), and SPP/
SPPL family members (10, 16, 23).
The latter are all defined by a critical
GXGD active site motif (1, 8, 9, 16).
Mutagenesis not only of the critical
aspartate but also of the glycine res-
idue immediately adjacent to the
aspartate residue affects -secretase
activity, by either blocking its activ-
ity or by modulating cleavage preci-
sion (9). Moreover, at least in PS1
the amino acid located at position X
of the GXGD domain is involved in
the final substrate selection at the
active site (48). Beside the con-
served GXGD and YD active site
domains, PS and SPP/SPPL family
members also share a conserved
PALmotif, which is likely to interact
with the catalytic center of GXGD-
type proteases (37). Numerous
FAD-associated mutations have
been identifiedwithin PS1 and some
within PS2 (46). All PS mutations
occur at evolutionary conserved
amino acids and apparently modu-
late the precision of -secretase
cleavage. Although the pathological
activity of PS mutations in terms of
increasing the A42:A40 ratio has
been known for a long time, the
molecular mechanisms behind
these consistent changes in proteolysis of APP are rather
unclear today. So far some studies implicate a structural change
of PS, because PS-associated FADmutations seem to affect the
distance between the N- and C-terminal fragments of PS (25).
Others implicate a loss of function, because PSmutations fail to
efficiently rescue a loss of the C. elegans homologue sel-12 (26,
27). Indeed at least the rather aggressive PS mutations exhibit
reduced overall A production when expressed in a complete
PS-free background (38). However, some PS1 mutations also
fully rescue the developmental abnormalities of a PS1 knockout
(29). To gain more insight into the mechanism of FAD-associ-
ated PS mutations and to understand intramembrane proteol-
ysis by GXGD-type proteases, we introduced the PS1 G384A
mutation at the corresponding position in SPPL2b. This muta-
tion was specifically chosen because the corresponding glycine
residue is fully conserved in all SPP/SPPLmembers (10, 11, 16),
whereas PSmutations outside of the GXGDmotif largely occur
at positions that do not share sequence conservation with SPP/
SPPL family members. Surprisingly, the introduction of this
FIGURE 5. TNF ICD conversion is catalyzed by SPPL2b. A, expression of SPPL2b D421A completely abol-
ishes TNF ICD production. Membranes of HEK 293 cells co-expressing TNF FL and the indicated SPPL2b
variants were incubated for 60 min at 37 °C, and ICD production was monitored as described in Fig. 2D. Note
that expression of the proteolytically inactive SPPL2b D421A completely abolishes ICD production. B, conver-
sion of the TNF ICDs is not related to nonspecific proteases. Membranes of HEK 293 cells co-expressing TNF
FL and SPPL2b wt were treated with either protease inhibitor mixture or vehicle and incubated for the indi-
cated time periods at 37 °C. Note that protease inhibitor treatment does not affect TNF ICD conversion.
C, (Z-LL)2-ketone treatment stabilizes TNF ICD intermediates. Membranes of HEK 293 cells co-expressing
TNF FL and SPPL2b wt were incubated for the indicated time periods at 37 °C. After 10-min incubation time
200 M (Z-LL)2-ketone or vehicle was added to the sample series. Note that after addition of (Z-LL)2-ketone the
turnover of TNF ICD species is blocked, whereas it proceeds in vehicle control-treated samples.
FIGURE 6. Selective reduction of A40 generation by PS1 G384A. -Secre-
tase complexes containing PS1 wt or PS1 G384A were isolated from HEK 293
cells and incubated with recombinant C100-His6 at 37 °C for the indicated
time periods. A peptides were separated as described (33) and detected
using the anti-A antibody 6E10. Note that A40 production is selectively
slowed by -secretase containing PS1 G384A as compared with PS1 wt.
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mutation into SPPL2b resulted in a slowed turnover of TNF
NTF, and the resulting longer TNF ICD species, whereas the
cleavage site of the secreted TNF C-domain was unaffected.
Thus, our findings provide strong evidence for the hypothesis
that the active site domains of SPP/SPPL family members are
not only reversed in their orientation as compared with PS (23)
but also act in a reversed manner. Consistent with the opposite
orientation of all known substrates for SPP/SPPL family mem-
bers (10, 12, 13, 15), our findings suggest that the TNF ICD
released into the cytosol topologically corresponds to the
secreted A-domain or similar peptides released from various
substrates by -secretase. The secreted C-domain on the other
handmay reflect an -like cleavage, which in the case of APP or
Notch would liberate the cytoplasmic APP KD or Notch ICD
(19–21).
Our in vitro experiments allowed for the first time a sensitive
time resolution of intramembrane proteolysis. This revealed a
stepwise sequential processing. Based on our findings longer
ICD species are sequentially turned over to shorter ICD species.
After an initiating -like cut, releasing the C-domain, further
cleavages occur, which result in the generation of smaller frag-
ments probably corresponding to a - and/or -like cleavage of
APP (22, 39, 40). Our findings suggest that the TNF substrate
may pass through a pore-like active site domain, or at least a
hydrophilic cavity, step-by-step, moving along the protease
active site, which itself remains locked at its original location.
Such a step-by-step mechanism may occur during or be sup-
ported by unfolding of the -helical conformation of the TM
domain of the substrate and explain how one substrate mole-
cule is cleaved multiple times by one and the same membrane-
embedded protease.
The in vitro experiments further demonstrated that cleav-
ages by wt or mutant SPPL2b were qualitatively similar if not
identical. These findings are therefore consistent with those
obtained with a mutant SPP variant (18). However, the appar-
ent accumulation of an elongated TNF ICD turned out to be
due to a reduced turnover rate of the mutant SPPL2b rather
than a change in cleavage specificity. This further explains why
for example after a 1-h incubation period SPPL2b G420A pro-
duces apparently longer ICD species than SPPL2b wt (see Fig.
2D). Extensive incubation times allowed mutant SPPL2b to
finally generate at least some ICDs, which were similar to those
produced by wt SPPL2b. Therefore, the FAD-like mutation of
SPPL2b surprisingly confers neither a full loss nor a gain of
function but, rather, reduces substrate turnover. This could be
mimicked when wt SPPL2b was incubated at low temperature.
Under these conditions reduced turnover also caused a relative
increase of larger ICD fragments over the shorter versions such
as those seen in SPPL2b G420A-expressing cells.
Similar findings were made for -secretase containing the
G384A mutant PS1. In that case, however, A40 generation
was selectively slowed bymutant -secretase as compared with
wt. Although A40 was still detectable, its production was sig-
nificantly reduced, and much longer incubation times were
needed to generate detectable levels of A40 (compare time
point 6 h in Fig. 6). Similar findings were recently described for
the PS1 I213T mutation, which also selectively affects A40
generation (49). Due to its rather aggressive behavior, strongly
altered cleavage specificity is observed for G384A with A42
considerably exceeding the amount of A40. However, no
apparent precursor-product relationship between A42 and
A40 was observed in the time-course analysis suggesting that
these peptidesmight be derived from two independent product
lines consistent with the model suggested by Qi-Takahara and
colleagues (22). This model implies two independent cleavage
events at the -cleavage site (at positions 49 and 48 of the A
domain) initiating two independent product lines. The initial
cut at position 49 is predicted to result in a trimming event
producing A46, A43, and A40, whereas the cut at position
48 results in products terminating at positions 45, 42, and 39.
Our findings suggest that the product line leading to A40 is
selectively slowed at least by an aggressive PS mutation,
whereas the A42-generating product line is unaffected ormay
even be increased. Selective reduction of A40 generation as a
cellular mechanism of FAD-associated PS mutations is also
consistent with recent findings demonstrating that A40 inter-
feres with A42 deposition in transgenic mice probably by
inhibiting its aggregation (50). Conformational interference
withA aggregation is also supported by the recent finding that
overexpression of cystatin C reduces A deposition (51). Thus
one may predict that FAD-associated PS mutations selectively
reduce the generation of an anti-amyloidogenicA species, and
thus accelerate A42 aggregation. Clearly, other PS mutations
in addition to the PS1G384A and I213Tmust be investigated to
further support this hypothesis. We have recently investigated
the PS1 L166Pmutation and again found slowedA40 produc-
tion5 as a cause for the change in the A42/A40 ratio. How-
ever, one should keep in mind that not all FAD-associated PS
mutations must result in a loss of A40 production. Week
mutations with a fairly late age of onset may show other mech-
anisms (and thus rescue a PS knockout phenotype; see above)
or the effects on A40 reduction may be too subtle to be inves-
tigated. Here we specifically investigated the very aggressive
PS1G384Amutation, because it occurs at a position that is fully
conserved in all members of the SPP/SPPL and PS family.
Our findings also have implications for the use of -secretase
as a therapeutic target. Multiple reports demonstrated that
robust inhibition of -secretase in vivo results in rather severe
side-effects due to the inhibition of the physiological function
of -secretase in Notch signaling (42, 52). Therefore, a window
allowing sufficient activity of -secretase for its physiological
function while reducing -secretase activity significantly
enough to slow A production needs to be defined. At too low
concentrations of -secretase inhibitors as well as upon termi-
nation of -secretase treatment in patients, increased A42
production may occur. This is indeed the case in patients
treated with -secretase inhibitors and in cells grown in the
presence of a low dose of certain -secretase inhibitors (for
review see Ref. 32). Thus such awindowmay bemuch narrower
than expected, and dosing of -secretase inhibitors needs to be
extremely carefully monitored to prevent opposite effects.
5 H. Steiner and C. Haass, submitted for publication.
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